← Leaderboards
Philip Jones
University Of Tx Md Anderson Can Ctr
$1,419,234
Attributed
$2,838,467
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $578.1K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,838,467 · 1
By mechanism
R01$2,838,467 · 1
Top collaborators
- John V. Heymach5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- John V. Heymach$11,138,593
- Anil K Sood$29,572,737
- Scott Kopetz$13,199,822
- Ferdinandos Skoulidis$4,461,361
- Rita Nahta$2,203,539
Others in their field
Other Emerging Leaders on “Genetically Engineered Mouse”
- Sonia Minikel Vallabh · Broad Institute, Inc.$16,658,654
- Jacqueline K White · Jackson Laboratory$11,774,050
- Jennifer M Munson · Virginia Polytechnic Inst And St Univ$6,798,191
- Sana D Karam · University Of Colorado Denver$6,190,968
- Stylianos Bournazos · Rockefeller University$6,003,276
- Magdalena Zernicka-Goetz · California Institute Of Technology$5,827,500
Research focus
Genetically Engineered MouseInsightAdverse EventBindingCancer PatientAffinityClassificationClinical DataCrystallographyDesignDiarrheaDoseDrug KineticsDrug ResistanceDrug ScreeningEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErbb2 GeneEvaluable DiseaseExanthemaExonsFda ApprovedGenerationsIn Silico
Grant awards (5)
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$549,195
R01 · FY2024 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$566,537
R01 · FY2023 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$566,537
R01 · FY2022 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$578,099
R01 · FY2021 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$578,099
R01 · FY2020 · CA